



CLINICAL COMPENDIUM

ACHIEVING CLINICAL BENEFIT WITH NONSTATIN THERAPIES AMONG HIGH-RISK PATIENTS — AVOIDING COMMON BARRIERS

References

Agarwala A, Liu J, Ballantyne CM, Virani SS. The use of risk enhancing factors to personalize ASCVD risk assessment: evidence and recommendations from the 2018 AHA/ACC Multi-society cholesterol guidelines. *Curr Cardiovas Risk Rep.* 2019;13(7):18. doi:10.1007/s12170-019-0616-y

D'Andrea E, Hey SP, Ramirez CL, Kesselheim AS. Assessment of the role of niacin in managing cardiovascular disease outcomes. A systematic review and meta-analysis. *JAMA Netw Open.* 2019;2(4):e192224. doi:10.1001/jamanetworkopen.2019.2224

Grundy SM, Stone NJ, Bailey AL, et al. 2018

AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation.* 2019;139(25): e1082-e1143. doi:10.1161/CIR0000000000000625

Hilleman DE, Vacek JL, Backes JM. Elevated Lp(a): Guidance for identifying and managing patients. *South Med J.* 117(4):208-213. doi:10.14423/SMJ.00000000000001675

Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol.* 2022;80(14):1366-1418. doi:10.1016/j.jacc.2022.07.006

National Lipid Association. Access to therapy. PCSK9 inhibitors. Published 2020. Accessed February 3, 2025. https://www.lipid.org/access_to_therapy

Prime Education LLC. Nonstatin prior authorization checklist. Published 2021. Accessed February 3, 2025. https://pcna.net/wp-content/uploads/2022/03/Nonstatin-Prior-Authorization-Checklist_2.pdf

Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: A scientific statement from the American Heart Association. *Arterioscler Thromb Vasc Biol.* 2022;42:e48–e60. doi:10.1161/ATV.0000000000000147

Tsimikas S, Marcovina SM. Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week. *J Am Coll Cardiol* 2022;80(9):934–946. doi:10.1016/j.jacc.2022.06.019

Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. *J Clin Lipidol.* 2019;13:374-392. doi:10.1016/j.jacl.2019.04.010